Overview

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and esophagogastric junction cancer previously untreated with chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Taiho Oncology, Inc.
Treatments:
Cisplatin
Fluorouracil
Tegafur